Liver Fat

Biomarker

Related News

Altimmune Advances Pemvidutide with FDA Breakthrough Designation and Phase 3 MASH Trial Planned

Mar 05, 2026

Altimmune's pemvidutide received FDA Breakthrough Therapy Designation for MASH treatment, with Phase 3 trial initiation planned for 2026. The company raised $75 million in January 2026 to fund development.

Can-Fite's Namodenoson Shows Promise in Pancreatic Cancer and Obesity Studies

Mar 04, 2026

Can-Fite BioPharma's drug candidate namodenoson met its primary endpoint in a Phase 2a pancreatic cancer trial and demonstrated anti-obesity effects in a peer-reviewed preclinical study published in the International Journal of Obesity.